Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00940589 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Phase 2 study, sponsored by Neurim Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT00940589 is a Phase 2 study that has completed, run by Neurim Pharmaceuticals. The registered enrollment target is 73 participants.
The verdict
NCT00940589, a Phase 2 study, has completed, sponsored by Neurim Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the acetylcholinesterase (AChE) inhibitor. The effects of add-on Circadin® 2mg vs. placebo on the decline in cognitive skills and global functioning, as well as on daytime somnolence and will be assessed.
Interventions
- DRUG Placebo
- DRUG Circadin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00940589
The ClinicalTrials.gov registry entry for NCT00940589 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurim Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00940589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00940589 about?
NCT00940589 is a clinical study titled "Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor". The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the acetylcholinesterase (AChE) inhibitor. The effects of add-on Circadin® 2mg vs. placebo on the decline in cognitive s...
What is the current status of trial NCT00940589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2009-09. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00940589?
The interventions under investigation include: Placebo (DRUG), Circadin (DRUG).
Who is sponsoring clinical trial NCT00940589?
This trial is sponsored by Neurim Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.